Your browser doesn't support javascript.
loading
Comparison of subsequent infusion hypersensitivity reactions to paclitaxel using two different infusion strategies.
Nymberg, Kristen; Folan, Stephanie; Berger, Michael; Li, Junan; Zanath, Kyle; VanDeusen, Jeffrey; Vargo, Craig.
Afiliación
  • Nymberg K; Department of Pharmacy, The Arthur G. James Cancer Hospital and Richard J. Solove Institute at The Ohio State University, 460 W 10th Avenue, C150, Columbus, OH, 43210, USA. Kristen.Nymberg@osumc.edu.
  • Folan S; Department of Pharmacy, The Arthur G. James Cancer Hospital and Richard J. Solove Institute at The Ohio State University, 460 W 10th Avenue, C150, Columbus, OH, 43210, USA.
  • Berger M; Department of Pharmacy, The Arthur G. James Cancer Hospital and Richard J. Solove Institute at The Ohio State University, 460 W 10th Avenue, C150, Columbus, OH, 43210, USA.
  • Li J; The Ohio State University College of Pharmacy, 500 West 12h Avenue, 214A Parks Hall, Columbus, OH, 43210, USA.
  • Zanath K; The Ohio State University College of Pharmacy, 500 West 12h Avenue, 214A Parks Hall, Columbus, OH, 43210, USA.
  • VanDeusen J; Division of Medical Oncology, The Ohio State University Wexner Medical Center, The Stefanie Spielman Comprehensive Breast Center, 1145 Olentangy River Road, Columbus, OH, 43212, USA.
  • Vargo C; Department of Pharmacy, The Arthur G. James Cancer Hospital and Richard J. Solove Institute at The Ohio State University, 460 W 10th Avenue, C150, Columbus, OH, 43210, USA.
Support Care Cancer ; 29(8): 4423-4429, 2021 Aug.
Article en En | MEDLINE | ID: mdl-33447864
PURPOSE: The purpose of this study was to compare the incidence of rescue medication utilization with up to 3 subsequent doses of paclitaxel in patients who underwent an infusion rate escalation versus those who continued on the standard infusion rate after experiencing an initial paclitaxel infusion hypersensitivity reaction (HSR) requiring rescue medications. METHODS: A retrospective, single-center review was conducted on patients who experienced a paclitaxel infusion HSR requiring rescue medications to their first or second lifetime dose of paclitaxel. RESULTS: A total of 99 patients were included for analysis, and from this group, 22 patients were continued on the standard infusion rate, while 77 patients were changed to an infusion rate escalation. The rate of subsequent rescue medication utilization was 5% in patients who were continued at the standard infusion rate versus 23% in patients who were changed to an infusion rate escalation (p = 0.064). The incidence of subsequent rescue medication utilization was unrelated to disease stage (p = 0.39), the paclitaxel dosing regimen (p = 0.99), or a diagnosis of asthma (p = 0.99). CONCLUSION: This single-center, retrospective study suggests that while not statistically significant, there was a potentially clinically meaningful increase in the rate of subsequent rescue medication utilization in patients who were changed to an infusion rate escalation compared to those who continued on the same standard infusion rate after experiencing an initial HSR to paclitaxel.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Paclitaxel / Hipersensibilidad a las Drogas Tipo de estudio: Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Support Care Cancer Asunto de la revista: NEOPLASIAS / SERVICOS DE SAUDE Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Paclitaxel / Hipersensibilidad a las Drogas Tipo de estudio: Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Support Care Cancer Asunto de la revista: NEOPLASIAS / SERVICOS DE SAUDE Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos